News & CommentHUNGARY

Bailout for Drug Research Institute

See allHide authors and affiliations

Science  17 Apr 1998:
Vol. 280, Issue 5362, pp. 372
DOI: 10.1126/science.280.5362.372

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


After the fall of the Iron Curtain, many Eastern European researchers abandoned their labs to find better jobs. Now a U.S. investment company and three partners have acquired a majority stake in a drug research institute in Budapest, Hungary, specializing in drugs for cardiovascular and central nervous system diseases. The companies hope to both develop the institute's own candidate drugs and serve Western drug firms looking for a way to test their products at lower cost.